TD Cowen raised the firm’s price target on TransMedics to $130 from $100 and keeps a Buy rating on the shares. The firm noted they raised their 2024 guidance as they have a multi-pronged plan to further propel growth, which includes three new clinical programs, one for OCS Lung and two for OCS Heart.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX: